Download video

AACR 2023 highlights on advances in the neoadjuvant treatment of resectable NSCLC with John Heymach

1.7K views

European Society for Medical Oncology (ESMO)

1 year ago

AACR 2023 highlights on advances in the neoadjuvant treatment of resectable NSCLC with John Heymach

AACR 2023 highlights on advances in the neoadjuvant treatment of resectable NSCLC with John Heymach

AACR 2023 highlights on advances in the neoadjuvant treatment of resectable NSCLC with John Heymach
3:44
AACR 2023 highlights on advances in the neoadjuvant treatment of resectable NSCLC with John Heymach
by European Society for Medical Oncology (ESMO)
AACR 2023 highlights on advances in the treatment of resected high-risk melanoma with Jeffrey Weber
3:40
AACR 2023 highlights on advances in the treatment of resected high-risk melanoma with Jeffrey Weber
by European Society for Medical Oncology (ESMO)
AACR 2023 highlights on advances in the treatment of hepatocellular carcinoma with Pierce Chow
3:29
AACR 2023 highlights on advances in the treatment of hepatocellular carcinoma with Pierce Chow
by European Society for Medical Oncology (ESMO)
AACR 2023 highlights on advances in the treatment of biliary tract cancer with Robin Katie Kelley
4:53
AACR 2023 highlights on advances in the treatment of biliary tract cancer with Robin Katie Kelley
by European Society for Medical Oncology (ESMO)
Dr Heymach on Updated AEGEAN Data in Resectable NSCLC
2:18
Dr Heymach on Updated AEGEAN Data in Resectable NSCLC
by OncLive
FDA Approves Durvalumab \/ Imfinzi for Resectable NSCLC Non-Small Cell Lung Cancer
2:43
FDA Approves Durvalumab \/ Imfinzi for Resectable NSCLC Non-Small Cell Lung Cancer
by OncologyTube
Lung Cancer Stage 4 :TAGRISSO (Tumor pill) Side Effects - visible after 9days
21:07
Lung Cancer Stage 4 :TAGRISSO (Tumor pill) Side Effects - visible after 9days
by Ivory's Diary
Lung Cancer New Treatment 2023
47:57
Lung Cancer New Treatment 2023
by Stanley Kim
ASCO 2023 Highlights on adjuvant osimertinib in resected EGFR mutated NSCLC: The ADAURA trial
6:20
ASCO 2023 Highlights on adjuvant osimertinib in resected EGFR mutated NSCLC: The ADAURA trial
by European Society for Medical Oncology (ESMO)
CRSF 07th Masterclass in Lung Cancer | Dr. Mounika Boppana on Neoadjuvant IO in Advanced NSCLC
17:18
CRSF 07th Masterclass in Lung Cancer | Dr. Mounika Boppana on Neoadjuvant IO in Advanced NSCLC
by CRSF - Cancer Research and Statistic Foundation
Neoadjuvant, Adjuvant, or Both: Individualized Perioperative Immunotherapy in Resectable NSCLC
48:44
Neoadjuvant, Adjuvant, or Both: Individualized Perioperative Immunotherapy in Resectable NSCLC
by PeerView Oncology
AACR 2023 highlights: why targeting KRAS is essential
0:29
AACR 2023 highlights: why targeting KRAS is essential
by VJOncology
ESMO 2023 highlights: advances in EGFR+ lung cancer second-line therapy
1:00
ESMO 2023 highlights: advances in EGFR+ lung cancer second-line therapy
by VJOncology
American Association for Cancer Research (AACR) 2023 Highlights from Community Oncology
8:38
American Association for Cancer Research (AACR) 2023 Highlights from Community Oncology
by OncBrothers: Practice-Changing Cancer Discussions
AACR 2023 Recap with Dr. Christopher Klebanoff
5:55
AACR 2023 Recap with Dr. Christopher Klebanoff
by Cancer Research Institute
Advancements in targeted therapies for oncogene-driven resectable NSCLC
1:17
Advancements in targeted therapies for oncogene-driven resectable NSCLC
by VJOncology
ASCO 2023 Expert Report on novelties in oncogene driven NSCLC by A. Curioni-Fontecedro
4:47
ASCO 2023 Expert Report on novelties in oncogene driven NSCLC by A. Curioni-Fontecedro
by European Society for Medical Oncology (ESMO)
Dr. Hilal Ozakinci at AACR 2023: Abstract No. 6642
2:49
Dr. Hilal Ozakinci at AACR 2023: Abstract No. 6642
by Moffitt Cancer Center
Perioperative Chemoimmunotherapy in Lung Cancer | NEJM
2:09
Perioperative Chemoimmunotherapy in Lung Cancer | NEJM
by NEJM Group
Expert Video Report on featured outcomes from novel NSCLC trials @AACR 2022
4:26
Expert Video Report on featured outcomes from novel NSCLC trials @AACR 2022
by European Society for Medical Oncology (ESMO)
Neoadjuvant therapy is taking off in lung cancer
1:25
Neoadjuvant therapy is taking off in lung cancer
by VJOncology